Pregled bibliografske jedinice broj: 1094413
A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis
A chromatographic approach to development of 5‑aminosalicylate/folic acid fxed‑dose combinations for treatment of Crohn’s disease and ulcerative colitis // Scientific reports, 10 (2020), 1; 20838, 10 doi:10.1038/s41598-020-77654-2 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1094413 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A chromatographic approach to development
of 5‑aminosalicylate/folic
acid fxed‑dose combinations
for treatment of Crohn’s disease
and ulcerative colitis
(A chromatographic
approach to development
of 5‑aminosalicylate/folic
acid fxed‑dose combinations
for treatment of Crohn’s disease
and ulcerative colitis)
Autori
Jeličić, Mario-Livio ; Brusač, Edvin ; Amidžić Klarić, Daniela ; Nigović, Biljana ; Turk, Nikša ; Mornar Ana
Izvornik
Scientific reports (2045-2322) 10
(2020), 1;
20838, 10
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
HPLC ; biomimetic chromatography ; assay
Sažetak
Medication adherence is an important factor in infammatory bowel disease therapy, which includes regular supplementation of malabsorbed vitamins. Absorption of folic acid is limited due to the damaging of the gastrointestinal tract, which can increase the chances to develop megaloblastic anaemia and colorectal cancer. In this work, 5- aminosalicylates (mesalazine, balsalazide, sulfasalazine and olsalazine) and folic acid were characterized regarding their pharmacokinetic related properties (hydrophobicity, phospholipid and plasma protein binding) using the biomimetic chromatographic approach. Despite the high binding percentage of 5-aminosalicylates for human serum albumin (> 61.44%), results have shown that folic acid binding to human serum albumin protein is far greater (69.40%) compared to α1-acid-glycoprotein (3.45%). Frontal analysis and zonal elution studies were conducted to provide an insight into the binding of folic acid to human serum albumin and potential competition with 5-aminosalicylates. The analytical method for the simultaneous determination of assay in proposed fxed-dose combinations was developed and validated according to ICH Q2 (R1) and FDA method validation guidelines. Separation of all compounds was achieved within 16 min with satisfactory resolution (Rs> 3.67) using the XBridge Phenyl column (150 × 4.6 mm, 3.5 µm). High linearity (r> 0.9997) and precision (RSD< 2.29%) was obtained, whilst all recoveries were within the regulatory defned range by British (100.0± 5.0%) and United States Pharmacopeia (100.0 ± 10.0%).
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Farmacija
POVEZANOST RADA
Projekti:
UIP-2017-05-3949 - Razvoj naprednih analitičkih metoda za lijekove i biološki aktivne tvari u liječenju upalnih bolesti crijeva (IBDAnalytics) (Mornar Turk, Ana, HRZZ - 2017-05) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Profili:
Ana Mornar Turk
(autor)
Daniela Amidžić Klarić
(autor)
Mario-Livio Jeličić
(autor)
Edvin Brusač
(autor)
Biljana Nigović
(autor)
Nikša Turk
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE